Clinical significance of elevated osteopontin levels in head and neck cancer patients

Auris Nasus Larynx

Volumn 34, Issue 3, 2007, Pages 343-346

  Eto, Mayumi ^a   Kodama, Satoru ^a   Nomi, Nozomi ^a   Uemura, Naoki ^a   Suzuki, Masashi ^a  

^a OITA UNIVERSITY   (Japan)

Author keywords

Biomarker; Head and neck cancer; Osteopontin; Serum

Indexed keywords

OSTEOPONTIN; SQUAMOUS CELL CARCINOMA ANTIGEN;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; CANCER PATIENT; CANCER STAGING; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; ENZYME IMMUNOASSAY; FEMALE; HEAD AND NECK CANCER; HISTOPATHOLOGY; HUMAN; MALE; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL;

ANTIGENS, NEOPLASM; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LARYNGEAL NEOPLASMS; LYMPHATIC METASTASIS; MALE; NEOPLASM STAGING; OSTEOPONTIN; PHARYNGEAL NEOPLASMS; SERPINS; STATISTICS; TUMOR MARKERS, BIOLOGICAL;

EID: 34249723210     PISSN: 03858146     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.anl.2006.11.012     Document Type: Article

References (22)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., Smigal C., et al. Cancer statistics. CA Cancer J Clin 56 (2006) 106-130
2. Thomas G.R., Nadiminti H., and Regalado J. Molecular predictors of clinical outcome in patients with head and neck squamous cell carcinoma. Int J Exp Path 86 (2005) 347-363
3. Standal T., Borset M., and Sundan A. Role of osteopontin in adhesion, migration, cell survival and bone remodeling. Exp Oncol 26 (2004) 179-184
4. Wai P.Y., and Kuo P.C. The role of osteopontin in tumor metastasis. J Surg Res 121 (2004) 228-241
5. Coppola D., Szabo M., Boulware D., Muraca P., Alsarraj M., Chambers A.F., et al. Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res 10 (2004) 184-190
6. Tuck A.B., O'Malley F.P., Singhal H., Harris J.F., Tonkin K.S., Kerkvliet N., et al. Osteopontin expression in a group of lymph node negative breat cancer patients. Int J Cancer 79 (1998) 502-508
7. Singhal H., Bautista D.S., Tonkin K.S., O'Malley F.P., Tuck A.B., Chambers A.F., et al. Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clin Cancer Res 3 (1997) 605-611
8. Fedarko N.S., Jain A., Karadag A., Van Eman M.R., and Fisher L.W. Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res 7 (2001) 4060-4066
9. Koopmann J., Fedarko N.S., Jain A., Maitra A., Iacobuzio-Donahue C., Rahman A., et al. Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma. Caner Epidemiol Biomark Prev 13 (2004) 487-491
10. Le Q.-T., Sutphin P.D., Raychaudhuri S., Yu S.C.T., Terris D.J., Lin H.S., et al. Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas. Clin Cancer Res 9 (2003) 59-67
11. Ue T., Yokozaki H., Kitadai Y., Yamamoto S., Yasui W., Ishikawa T., et al. Co-expression of osteopontin and CD44v9 in gastric cancer. Int J Cancer 79 (1998) 127-132
12. Saitoh Y., Kuratsu J., Takeshima H., Yamamoto S., and Ushio Y. Expression of osteopontin in human glioma. Its correlation with the malignancy. Lab Investig 72 (1995) 55-63
13. Crawford H.C., Matrisan L.M., and Liaw L. Distinct roles of osteopontin in host defense activity and tumor survival during squamous cell carcinoma progression in vivo. Cancer Res 58 (1998) 5206-5215
14. Devoll R.E., Li W., Woods K.V., Pinero G.J., Butler W.T., Farach-Carson M.C., et al. Osteopontin (OPN) distribution in premalignant and malignant lesions of oral epithelium and expression in cell lines derived from squamous cell carcinoma of the oral cavity. J Oral Pathol Med 28 (1999) 97-101
15. Schneider S., Yochim J., Brabender J., Uchida K., Danenberg K.D., Metzger R., et al. Osteopontin but not osteonectin messenger RNA expression is a prognostic marker in curatively resected non-small cell lung cancer. Clin Cancer Res 10 (2004) 1588-1596
16. Yasumatsu R., Nakashima T., Azuma K., Hirakawa N., Kuratomi Y., Tomita K., et al. SCCA1 expression in T-lymphocytes peripheral to cancer cells is associated with the elevation of serum SCC antigen in squamous cell carcinoma of the tongue. Cancer Lett 167 (2001) 205-213
17. Mor G., Visintin I., Lai Y., Zhao H., Schwarz P., Rutherford T., et al. Serum protein markers for early detection of ovarian cancer. Proc Natl Acad Sci USA 102 (2005) 7677-7682
18. Leo C., Giaccia A.J., and Denko N.C. The hypoxic tumour microenvironment and gene expression. Semin Radiat Oncol 14 (2004) 207-214
19. Hockel M., and Vaupel P. Tumor hypoxia. definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 93 (2001) 266-276
20. Brown J.M., and Wilson W.R. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 4 (2004) 437-447
21. Nordsmark M., Bentzen S.M., Rudat V., Brizel D., Lartigau E., Stadler P., et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol 77 (2005) 18-24
22. Overgaard J., Eriksen J.G., Nordsmark M., Alsner J., and Horsman M.R. Plasma osteopontin, hypoxia, and response to the hypoxia sensitizer nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomized double-blind placebo-controlled trial. Lancet Oncol 6 (2005) 757-764